Cryoport, Inc. (CYRX) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Cryoport, Inc. is a global provider of temperature-controlled supply chain solutions for the life sciences industry, focusing on regenerative medicine. The company operates two primary segments: Life Sciences Services and Life Sciences Products. A material event during the period was the announcement of a definitive agreement to divest its CRYOPDP specialty courier business to DHL Supply Chain, classified as discontinued operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $41.0 million | $37.3 million |
| Gross Margin | $18.6 million (45.4%) | $15.1 million (40.4%) |
| Net Loss (GAAP) | $(12.0) million | $(18.9) million |
| Net Loss Attributable to Common Stockholders | $(14.0) million | $(20.9) million |
| Adjusted EBITDA | $(2.8) million | $(6.7) million |
| Cash and Cash Equivalents | $36.1 million | $34.1 million |
| Short-Term Investments | $207.9 million | $216.5 million |
| Working Capital | $337.2 million | $277.0 million |
| Convertible Senior Notes Outstanding | $200.5 million (Principal) | $200.5 million (Principal) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10.1% year-over-year. Life Sciences Services revenue grew 17.3% to $22.9 million, driven by a 22.8% increase in BioStorage/BioServices and 32.9% growth in Commercial Cell & Gene therapy revenue. Life Sciences Products revenue grew 2.1% to $18.2 million.
- Profitability Improvement: Net loss narrowed by 36.6% to $12.0 million. Loss from continuing operations decreased by 39.8% to $9.0 million. Adjusted EBITDA improved significantly from a loss of $6.7 million to $2.8 million.
- Margin Expansion: Gross margin percentage improved from 40.4% to 45.4%, driven by better performance in both services (47.9%) and products (42.3%) segments.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 13.0% to $24.2 million, primarily due to a $5.2 million gain from the change in fair value of contingent consideration and lower stock-based compensation. Engineering and development expenses fell 17.2%.
- Divestiture: The CRYOPDP business was reclassified as discontinued operations. Revenue from this segment was $17.1 million, with a net loss of $3.0 million for the quarter.
Guidance, Outlook, and Risks
- Strategic Divestiture: On March 31, 2025, Cryoport entered a Sale and Purchase Agreement to sell CRYOPDP to DHL for an enterprise value of $195 million (approx. $138 million cash plus debt repayment). Closing is expected in Q2 or Q3 2025, subject to regulatory approvals. This is expected to enhance focus on EMEA and APAC regions.
- Liquidity: Management believes current cash, short-term investments ($244.0 million total), and projected cash flows will satisfy operational requirements for at least the next 12 months. The company has $73.9 million remaining in stock repurchase authorization.
- Debt Obligations: The company has $14.3 million in 2025 Convertible Senior Notes due in June 2025 and $186.2 million in 2026 Convertible Senior Notes due in December 2026.
- Risks: Key risks include the successful closing of the DHL transaction, regulatory approvals, foreign currency fluctuations (which negatively impacted revenue by $0.3 million in constant currency terms), and the ability to secure additional capital if needed.
Investor Verification Checklist
- Transaction Closing: Verify the status of regulatory approvals for the CRYOPDP divestiture to DHL and the expected closing timeline.
- Debt Maturity: Confirm the company's plan for refinancing or repaying the $14.3 million 2025 Convertible Senior Notes due in June 2025.
- Discontinued Operations: Review the specific financial impact of the CRYOPDP divestiture on future cash flows and the terms of the transitional services agreement with DHL.
- Constant Currency Impact: Assess the sensitivity of future revenue to foreign exchange rates, particularly in EMEA and APAC regions.
- Contingent Consideration: Monitor the fair value adjustments related to contingent consideration from past acquisitions, which significantly impacted SG&A expenses this quarter.